LINKÖPING, Sweden; February 5, 2019 – AMRA Medical announces the addition of Allison Robbins, CFA to its leadership team. Robbins will serve as Chief Financial Officer on a part-time basis located in the U.S. as the company looks to expand its commercial partnership reach and fundraising efforts.
Ms. Robbins brings extensive experience from both sides of the investment discussion. During her time at several healthcare-focused investment funds, including Genzyme Ventures, Tullis Health Investors, and Paramount Capital, she completed eight venture capital investments in transformative medical technologies resulting in six IPOs and two M&A transactions and several products on the market or in late-stage clinical development. She has also worked on behalf of numerous operating companies to craft strategy, develop long-range financial forecasts, negotiate transactions, and advance fundraising efforts. Ms. Robbins has also served in foundational operating roles with a U.S. direct-pay primary care practice and a health tech SaaS start-up.
In addition to her role at AMRA Medical, Robbins has been and will continue to provide financial and strategy consulting services to venture capital funds, accelerators, and startups via Green Shoots Consulting, LLC, with a focus on the biotech, device, and digital health industries. Her recent work with large pharmaceutical companies centers on the commercial and research applications of real-world data (RWD) and modern analytics in the medical field.
Ms. Robbins received her MBA with Honors from The Wharton School in Health Care Management and Finance, and her BA, Summa Cum Laude, in Biochemistry and Economics from Dartmouth College. She is a CFA® charterholder.
AMRA Medical’s CEO, Eric Converse, is pleased to have Ms. Robbins on the team:
“I’ve known Allison for several years and have worked with her on various investment scenarios in the health tech space. I knew I would be reaching out to her when I joined AMRA, as I have been continuously impressed with her abilities. Allison can quickly grasp concepts and deploy them into creative business models. Her financial discipline combined with her creative commercial strategy will be a great asset for AMRA as we advance the commercialization of our technology.”
Allison joins the AMRA team at a pivotal moment in the company’s history. The AMRA® Profiler recently received FDA clearance for clinical use and 2018 sales had a very strong finish. The team looks forward to continued and growing collaborations with its customers.